Yissum, the technology transfer company of the Hebrew University of Jerusalem, introduced a novel device that enhances the diagnostic value of saliva.
Two researchers at Hebrew University of Jerusalem have designed synthetic molecules that may have future implications for the development of a new family of anti-cancer drugs.
Dr. Arie Dagan and Prof. Shimon Gatt have developed molecules that kill cancers without affecting normal tissue. The technology is patented and commercialized by Yissum, the Technology Transfer Company of the Hebrew University.
Où Va Le Biopartnering Franco-Israélien ?
A point of view on Israel's Biotech industry by Start Up Magazine
An Israeli professor has developed a new saliva-based disposable device that could be used to increase the diagnostic value of saliva, enabling physicians to do away with blood and other invasive diagnostic tests.
Yissum's technologies presented at Biomed 2008: An Assay and Kit and Device for Removing Amylase from Body Fluids and A Novel Anti-Inflammatory Agent
Economist: HUJI researcher Boris Rubinsky and his colleagues at Berkeley think they could help make medical imagining simpler, cheaper and more widely available. His team report in a recent issue of Public Library of Science (PloS) ONE on a design to use mobile phones to send raw imaging data to a base where it could be processed with the sophisticated software needed to create a medical image. The image could then be returned to the mobile phone and viewed on it. The mobile phone may join the stethoscope and the thermometer as an indispensable piece of medical kit.
Israeli Technology Transfer companies have become a role model for foreign academic institutes.
In 2006 researchers from the Hebrew University in Israel isolated a variant of the virus that causes Newcastle disease, a highly contagious disease in birds that can kill. This variant was able to target selectively cancer cells in humans. Trials on a form of aggressive primary brain tumour have shown one complete regression out of 14 treated patients.
Sophisticated medical images such as MRI and ultrasound scans and x-rays can be sent via cellular phones using a process developed at the Hebrew University of Jerusalem. The new technology, jointly owned by Yissum and the University of California is expected to be a boon not only for patients in developed counties, including rural areas with reduced access to medical services, but especially for those in the Third World.
Hybridization of biological and electric systems can serve as the basis for diverse applications ranging from biosensors and drug screening systems to neuro-electronic computers. Our technology enables the hybridization by creating an innovative physical linkage between cells and surface substrates, and using ion-sensitive field- effect transistors (ISFET) to transform the biological activity into readable electronic signals
Hebrew University researchers have recently developed a bio-electronic sensor for the detection of chemicals such as nerve gases and insecticides by irreversible inhibition of the enzyme acetylcholine esterase.
The Israeli start-up company, Nanolymf Ltd, believes its technology has the potential to allow the oral administration of some of the biggest intravenous and injectable drugs on today’s market.
Instead of asking friends "How do you feel?" or doctors examining patients, one day such queries and examinations may be replaced by tiny radio antennas implanted under the skin to act as remote sensors of humans' emotional, physiological state. Scientists at the Hebrew University's applied physics department have discovered a method for remote sensing of people's physiological and emotional state.
Recent research conducted by Dr. Hermona Soreq and co-workers at the
Alexander Silberman Life Sciences Institute at The Hebrew University of
Jerusalem, in collaboration with PharmAthene, examined the role of rBChE in
the prevention of amyloid plaques, which are believed to play a role in the
development of Alzheimer's disease.
The innovative cationic emulsion for the treatment of dry eye symptoms is the first product developed from its pipeline to be marketed
The company raised the finance from Docor International, Moshe (Mori) Arkin and a number of undisclosed institutional investors.